ARA-290 vs SS-31

Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing

ARA 290 (cibinetide) is a synthetic 11-amino-acid peptide derived from the helix B region of erythropoietin (EPO), engineered to activate the innate repair receptor (IRR) — a tissue-protective heteroreceptor complex comprising the EPO receptor and the β-common receptor (CD131) — without engaging the classical erythropoietic EpoR homodimer, thereby separating EPO's tissue-protective signaling from its hematopoietic effects. By selectively engaging the IRR rather than the erythropoietic receptor, cibinetide activates anti-inflammatory and anti-apoptotic intracellular pathways in neurons, endothelium, and other metabolically active tissues without causing erythrocytosis, hypertension, or thrombosis, making it a candidate for neuropathy and inflammatory tissue injury contexts. Randomized, double-blind Phase 2 clinical trials have demonstrated that cibinetide improves metabolic control and neuropathic symptom scores in patients with type 2 diabetes, and a separate study demonstrated improved corneal nerve fiber abundance in patients with sarcoidosis-associated small fiber neuropathy — providing human proof-of-concept for both diabetic and inflammatory peripheral neuropathy applications. Cibinetide (ARA 290) is an investigational compound that has not received FDA approval for any indication; Phase 2 data supports further investigation in peripheral neuropathies, but no Phase 3 completion or regulatory filing has occurred as of 2025.

Targets cardiolipin in inner mitochondrial membrane; stabilizes cristae structure; enhances electron transport chain efficiency; reduces mitochondrial ROS

SS-31 (elamipretide; Szeto-Schiller peptide 31; MTP-131; bendavia) is a synthetic cardiolipin-targeting tetrapeptide that selectively concentrates in the inner mitochondrial membrane through electrostatic interaction with cardiolipin, where it stabilizes cristae ultrastructure, preserves electron transport chain assembly, and reduces mitochondrial reactive oxygen species production to protect against ischemic and metabolic mitochondrial injury. By binding cardiolipin at the inner mitochondrial membrane, SS-31 maintains the protein-lipid interactions required for efficient electron transport chain supercomplex formation, preserving cytochrome c association with complexes I–IV, reducing electron leak, and sustaining the proton gradient required for ATP synthase activity — thereby protecting energy production in cardiomyocytes, neurons, and renal tubular cells under ischemic or oxidative stress. A randomized, placebo-controlled trial published in Circulation Heart Failure demonstrated that elamipretide improved cardiac function in patients with heart failure with reduced ejection fraction, and a Phase 2a trial published in Circulation Cardiovascular Interventions provided additional human evidence of mitochondrial protection in the context of renal artery stenosis revascularization. Elamipretide has not received FDA approval; it has received rare pediatric disease designation for Barth syndrome and has been studied in multiple Phase 2 trials including heart failure, primary mitochondrial myopathy, and geographic atrophy, with ongoing Phase 3 development programs as of 2025.